Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:36:36.317Z.
Calculation as of: 2026-10-06T19:36:36.317Z.
Quote observation: 2026-10-06T19:35:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1f516b86ce6f8a32b007838909cf85d374f635633f340bc308fa792387434ce1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$266.00M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$268.81M
EV/EBIT Ratio
N/A
TTM Avg
27.51x
3Y Avg
26.71x
5Y Avg
33.46x
Market Cap
$263.41M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$269.18M
EV/EBIT Ratio
N/A
TTM Avg
102.60x
3Y Avg
102.60x
5Y Avg
102.60x
Market Cap
$264.68M
EV/EBIT Ratio
N/A
TTM Avg
2223.35x
3Y Avg
2223.35x
5Y Avg
2223.35x
Market Cap
$271.35M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.17M
EV/EBIT Ratio
N/A
TTM Avg
11.31x
3Y Avg
11.31x
5Y Avg
15.93x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fate Therapeutics, Inc. (FATE) | $266.34M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $266.00M | N/A | N/A | N/A | N/A |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $268.81M | N/A | 27.51x | 26.71x | 33.46x |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.41M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $269.18M | N/A | 102.60x | 102.60x | 102.60x |
| Treace Medical Concepts, Inc. (TMCI)vs › | $264.68M | N/A | 2223.35x | 2223.35x | 2223.35x |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.35M | N/A | N/A | N/A | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $261.17M | N/A | 11.31x | 11.31x | 15.93x |
| OraSure Technologies, Inc. (OSUR)vs › | $261.28M | N/A | 5.32x | 26.78x | 44.78x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
